Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158850 | 0.91 | PARP10 (0.52) | PARP10ALDH1A1NPSR1NPC1RAB9A | |
| SCHEMBL1360792 | 0.79 | ALDH1A1 (0.50) | ALDH1A1NPSR1HPGDSMN1; SMN2GPR88 | |
| SCHEMBL1362522 | 0.78 | TACR1 (0.55) | GPR88 | |
| SCHEMBL1362244 | 0.76 | CYP3A4 (0.47) | ALDH1A1 | |
| SCHEMBL6617399 | 0.75 | ACE (0.46) | — | |
| SCHEMBL1362526 | 0.75 | CTSS (0.41) | NPSR1SMN1; SMN2 | |
| SCHEMBL8268336 | 0.75 | NPC1 (0.77) | PARP10NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL12502477 | 0.74 | PARP10 (0.65) | PARP10ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL1363688 | 0.74 | CNR2 (0.46) | ALDH1A1NPSR1HPGDSMN1; SMN2GPR88 | |
| SCHEMBL1362561 | 0.73 | HPGD (0.56) | ALDH1A1NPSR1HPGDSMN1; SMN2GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501813-B1 | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | ALBIREO AB (SE) | 2013-08-14 | — | — | EP | disclosed |
| US-8067584-B2 | Benzothiazepine derivatives | ALBIREO AB (SE) | 2011-11-29 | — | — | US | disclosed |
| EP-1430040-B1 | BENZOTHIAZEPINE DERIVATIVES | ALBIREO AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-7238684-B2 | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7192946-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | ALBIREO AB (SE) | 2006-05-04 | — | — | US | disclosed |
| EP-1597245-A1 | BENZOTHIAZEPINE AND BENZOTHIEPINE DERIVATIVES | AstraZeneca AB (SE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050143368-A1 | Chemical compounds | ALBIREO AB (SE) | 2005-06-30 | — | — | US | disclosed |
| EP-1501813-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040254160-A1 | Benzothiazepine derivatives | ELOBIX AB (SE) | 2004-12-16 | — | — | US | disclosed |
| WO-2004076430-A1 | BENZOTHIAZEPINE AND BENZOTHIEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-09-10 | — | — | WO | disclosed |
| EP-1430040-A1 | BENZOTHIAZEPINE DERIVATIVES | Astrazeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003091232-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003020710-A1 | BENZOTHIAZEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143368-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | PARP10 4122/4885ALDH1A1 1675/4885NPSR1 716/4885 |
| US-20040254160-A1 | Benzothiazepine derivatives | SLC10A2, SLC10A1, ABCB11 | PARP10 3722/4885ALDH1A1 941/4885NPSR1 1475/4885 |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | SLC10A2, SLC10A1, ABCB11 | PARP10 3739/4885ALDH1A1 1730/4885NPSR1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.